Humedix
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Humedix makes hyaluronic acid-based dermal fillers, injectable gels used to smooth wrinkles and restore facial volume, as well as injections that treat joint pain from arthritis.
Its products reach clinics, hospitals, and cosmetic practitioners in both the domestic South Korean market and internationally. Listed on KOSDAQ, South Korea's tech and small-cap exchange, the company operates two distinct divisions: an aesthetics unit covering fillers, a botulinum toxin product, cosmetics, and skin-care devices, and a contract manufacturing unit that produces prescription drugs, eye drops, and active pharmaceutical ingredients.
Summary is AI-generated and may contain errors · figures from DART filings
The company's contract manufacturing division produces finished pharmaceuticals and raw active ingredients, meaning it serves both its own branded product lines and third-party pharmaceutical clients.
Humedix in five facts
What does Humedix do?
Humedix makes hyaluronic acid-based dermal fillers, injectable gels used to smooth wrinkles and restore facial volume, as well as injections that treat joint pain from arthritis.
Where is Humedix listed and in which sector?
Humedix (Korean name: 휴메딕스) trades under KRX code 200670 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Humedix?
Its market capitalisation was US$199.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Humedix's latest annual revenue and operating profit?
For fiscal year 2025, Humedix reported revenue of US$128.3M, operating profit of US$31.9M and net income of US$39.1M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 5.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meetingOct 21
- Share cancellation decisionSep 10
- Treasury share trust terminated: results reportSep 9
- Treasury share acquisition via trust: status reportSep 9
- Cash/in-kind dividend decision (quarterly dividend)
Humedix declared a cash dividend of US$0.14 per share, equal to about 0.74% of the recent share price.
Dividend · Aug 11 - Cash/in-kind dividend decision
Humedix declared a cash dividend of US$0.13 per share, equal to about 0.59% of the recent share price.
Dividend · May 12 - [Amended] Cash/in-kind dividend decision
Humedix updated its declared cash dividend of US$0.14 per share, equal to about 0.49% of the recent share price.
Dividend · Apr 13 · 2 versions - Change of less than 30% in revenue or profit/loss structure (15% for large companies) (voluntary)
Humedix reported separate results for FY2025: revenue of US$118M (+5.1% year on year), operating profit of US$29.4M (−1.9% year on year) and net income of US$34.7M (+27.2% year on year).
Earnings · Feb 13